Zobrazeno 1 - 10
of 364
pro vyhledávání: '"Refractory Chronic Lymphocytic Leukemia"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Alicia Enrico, Viktor Komlosi, Mary Ann Anderson, Kavita Sail, Ewa Lech-Marańda, Madhavi Pai, Shang-Ju Wu, Tara Cochrane, Tadeusz Robak, Robert Weinkove, Nikitin Ea, Evgueniy Hadjiev, John Pesko, David Gómez-Almaguer, Tamás Masszi
Publikováno v:
Leukemia & Lymphoma. 63:304-314
Venetoclax, a potent B-cell lymphoma-2 (BCL-2) inhibitor, has demonstrated clinical efficacy in chronic lymphocytic leukemia (CLL). VENICE II is an open-label, single-arm, phase 3b study (NCT02980731) evaluating the impact of venetoclax monotherapy (
Autor:
Otavio C. G. Baiocchi, Karin Zattar Cecyn, Mariana de Oliveira Marques, Milena Almendra Rodrigues, Fabio Nascimento Brito
Publikováno v:
Blood research
Publikováno v:
Clinical and Experimental Medicine. 22:161-171
Recently, the use of novel targeted drugs significantly improved the overall response rate (ORR) and survival of patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL). The treatment of R/R CLL has been gradually developed from trad
Autor:
Bartosz Pula, Ewa Bodzenta, Dorota Zdunczyk, Małgorzata Rydzanicz, Iwona Sokolowska-Giezgala, Katarzyna Warzybok, Marcin M Machnicki, Magdalena Olszewska-Szopa, Anna Labedz, Jolanta Wieczorek, Dominika Wisniewska-Organek, Tomasz Stoklosa, Kamila Kruczkowska-Tarantowicz, Krzysztof Jamroziak, Marek Dudziński, Zofia Spyra-Gorny, Rafał Płoski, Dariusz Kumorek, Monika Pepek, Alina Urbanowicz, Elzbieta Morawiec-Szymonik, Agnieszka Szeremet, Pawel Bernatowicz, Agnieszka Pollak, Ryszard Wichary, Waldemar Tomczak
Publikováno v:
Acta Haematologica Polonica. 52:94-102
Indtroduction and methods: In chronic lymphocytic leukemia (CLL), molecular and cytogenetic diagnostics are crucial for the determination of accurate prognosis and treatment choice. Among different genetic aberrations, del(17p13) or TP53 mutations co
Autor:
Dionne Smith, Daniela Maier, Stephen E. Spurgeon, Alexey V. Danilov, Anne Marie Quinson, Tanya Siddiqi, Jennifer R. Brown
Publikováno v:
Investigational New Drugs
SummaryBI 836826 is a chimeric immunoglobulin G1 antibody targeting CD37, a transmembrane protein expressed on normal and malignant B cells. This open-label, phase Ib, dose-escalation study was conducted to determine the recommended phase II dose (RP
Publikováno v:
Expert Review of Anticancer Therapy. 21:481-488
Introduction: The treatment landscape of chronic lymphocytic leukemia (CLL) has changed dramatically with the introduction of novel targeted therapies. Phosphoinotiside-3 kinase (PI3K) is a B-cell receptor-associated kinase that is essential for grow
Autor:
Akiko Konishi, Shosaku Nomura, Atsushi Satake, Tomoki Ito, Takahisa Nakanishi, Hideaki Yoshimura, Shinya Fujita, Masaaki Hotta
Publikováno v:
Journal of Blood Medicine
There have been few reports on central nervous system (CNS) involvement in chronic lymphocytic leukemia (CLL). This is an extremely rare disease with poor prognosis, owing to resistance to various treatments. We describe a 33-year-old man with intrac
Autor:
Kerry A. Rogers, David M. Weiss, Ying Huang, Jennifer A. Woyach, Lynne V. Abruzzo, Nyla A. Heerema, Christin Banks, Allison Dean, Cara Grantier, Barbara L. Andersen, Margaret S. Lucas, Jeffrey A. Jones, Gerard Lozanski, Seema A. Bhat, John C. Byrd, Farrukh T. Awan, Kami J. Maddocks, Amy S. Ruppert, Thomas R. Valentine
Publikováno v:
J Clin Oncol
PURPOSE The development of highly effective targeted agents for chronic lymphocytic leukemia offers the potential for fixed-duration combinations that achieve deep remissions without cytotoxic chemotherapy. PATIENTS AND METHODS This phase II study te